Feb 27, 2019 - CytomX Therapeutics (NASDAQ:CTMX) Q4 2018 Earnings Conference Call February 27, 2019, 5:00 pm ET Company Participants Chris Keenan - VP, IR Sean McCarthy - President, CEO & Chairman Debanjan Ray -
Feb 20, 2019 - CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nov 15, 2018 -
Nov 11, 2018 - Start Time: 17:00 End Time: 17:34 CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2018 Earnings Conference Call November 06, 2018, 17:00 PM ET Executives Sean McCarthy - President and CEO Debanjan Ray - CF
Jul 17, 2018 - The biotechnology sector is fertile ground for highly profitable investments, but the downside risk in the sector is also above average.Since the dispersion in returns is so wide, picking the right in
Jul 13, 2018 - CytomX Therapeutics (NASDAQ:CTMX) priced public offering of 5.10M common at $24.50/share for gross proceeds of $125M.Underwriters have a 30-day option to purchase up to an additional 765,306 shares o
May 26, 2018 - AbbVie is about to change the CLL game again?Little Krystal Biotech looks to attack epidermolysis bullosa.CytomX allowed to unleash its probody drug conjugate on cancer.
May 20, 2018 - CytomX bounced wonderfully off its 200-day MA.Their presentation at ASCO was well-received.CytomX is a momentum stock that appears well-positioned for additional appreciation.Now is probably a prudent
May 18, 2018 - The following slide deck was published by CytomX Therapeutics in conjunction with this event.
May 09, 2018 - ImmunoGen is powering a highly enriched pipeline of antibody conjugate drug (“ADC”) for the stellar cancer treatment. ADC enables the efficient killing of cancer cells while minimizing the toxic effec